The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin, glofitamab, or mosunetuzumab, and to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) for the combinations.
Male or female participant aged 18 years or older
Pathologic diagnosis of relapsed (disease that has recurred following a response) or refractory (disease that failed to respond to prior therapy) B-NHL (2016 World Health Organization classification) who have failed, or been intolerant to any approved therapy and had received at least two systemic treatment regimens in Part 1; and at least one systemic treatment regimen in Part 2
DLBCL, not otherwise specified (NOS)
Germinal Center B-cell type
Known history of hypersensitivity resulting in treatment discontinuation to or positive serum human ADA to a CD19 antibody
Previous therapy with loncastuximab tesirine
Previous treatment with polatuzumab vedotin, glofitamab or mosunetuzumab (applied to relevant arm and/or cohort of the specific drug administered)
Participants who received previous treatment of polatuzumab vedotin containing regimen will be excluded from Arm C
6
Treatment groupsSee each treatment group below.
ADC Therapeutics S.A.
Lead sponsor